These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20824046)

  • 1. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
    Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
    Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice.
    Ren Y; Fleischmann D; Foygel K; Molvin L; Lutz AM; Koong AC; Jeffrey RB; Tian L; Willmann JK
    Invest Radiol; 2012 Jan; 47(1):25-32. PubMed ID: 22178893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
    Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
    Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
    Bradley DP; Tessier JL; Checkley D; Kuribayashi H; Waterton JC; Kendrew J; Wedge SR
    NMR Biomed; 2008 Jan; 21(1):42-52. PubMed ID: 17458919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
    Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
    Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.
    Gule MK; Chen Y; Sano D; Frederick MJ; Zhou G; Zhao M; Milas ZL; Galer CE; Henderson YC; Jasser SA; Schwartz DL; Bankson JA; Myers JN; Lai SY
    Clin Cancer Res; 2011 Apr; 17(8):2281-91. PubMed ID: 21220477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
    Wachsberger P; Burd R; Ryan A; Daskalakis C; Dicker AP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):854-61. PubMed ID: 19801101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).
    Siemann DW; Norris CM; Ryan A; Shi W
    Anticancer Res; 2009 Jun; 29(6):1987-92. PubMed ID: 19528456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
    Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
    Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
    Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
    Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
    Troiani T; Serkova NJ; Gustafson DL; Henthorn TK; Lockerbie O; Merz A; Long M; Morrow M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2007 Nov; 13(21):6450-8. PubMed ID: 17975157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility and comparison of DCE-MRI and DCE-CT perfusion parameters in a rat tumor model.
    Ng CS; Waterton JC; Kundra V; Brammer D; Ravoori M; Han L; Wei W; Klumpp S; Johnson VE; Jackson EF
    Technol Cancer Res Treat; 2012 Jun; 11(3):279-88. PubMed ID: 22417064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
    Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.
    Wang H; Lutz AM; Hristov D; Tian L; Willmann JK
    Radiology; 2017 Feb; 282(2):443-452. PubMed ID: 27490690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
    Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
    Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.
    Cesca M; Frapolli R; Berndt A; Scarlato V; Richter P; Kosmehl H; D'Incalci M; Ryan AJ; Giavazzi R
    Neoplasia; 2009 Nov; 11(11):1155-64. PubMed ID: 19881951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model.
    Choi S; Sano D; Cheung M; Zhao M; Jasser SA; Ryan AJ; Mao L; Chen WT; El-Naggar AK; Myers JN
    Clin Cancer Res; 2008 Aug; 14(16):5081-9. PubMed ID: 18698025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer.
    Bhattacharya A; Turowski SG; San Martin ID; Rajput A; Rustum YM; Hoffman RM; Seshadri M
    Anticancer Res; 2011 Feb; 31(2):387-93. PubMed ID: 21378316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.